[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576142":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":21,"responsibleParty":76,"collaborators":7,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":80,"sex":86,"minAge":87,"maxAge":7,"enrollmentInfo":88,"targetDuration":7,"studyType":91,"phases":7,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Pier Luigi Zinzani, MD","PRINCIPAL_INVESTIGATOR",[13,17],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+390512144042","pierluigi.zinzani@unibo.it",{"name":18,"role":14,"phone":19,"phoneExt":7,"email":20},"Cinzia Pellegrini, MD","+390512143680","cinzia.pellegrini@aosp.bo.it",[22,39,57],{"facility":23,"status":24,"city":25,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"IRCCS Azienda Ospedaliero - Universitaria di Bologna","RECRUITING","Bologna","40138","Italy","IT",{"type":30,"coordinates":31},"Point",[32,33],11.33875,44.49381,{"lat":33,"lon":32},[36,37,38],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},{"name":18,"role":14,"phone":19,"phoneExt":7,"email":20},{"name":10,"role":11,"phone":7,"phoneExt":7,"email":7},{"facility":40,"status":24,"city":41,"state":7,"zip":42,"country":27,"countryCode":28,"cosmosGeoPoint":43,"geoPoint":47,"contacts":48},"Azienda Ospedaliera Universitaria- POLICLINICO BARI","Bari","70124",{"type":30,"coordinates":44},[45,46],16.86982,41.12066,{"lat":46,"lon":45},[49,53,56],{"name":50,"role":14,"phone":51,"phoneExt":7,"email":52},"Pellegrino Musto, MD","+39 0805593471","pellegrino.musto@uniba.it",{"name":54,"role":14,"phone":7,"phoneExt":7,"email":55},"Francesco Gaudio, MD","francesco.gaudio@policlinico.ba.it",{"name":50,"role":11,"phone":7,"phoneExt":7,"email":7},{"facility":58,"status":24,"city":59,"state":7,"zip":60,"country":27,"countryCode":28,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Fondazione IRCCS Istituto Nazionale dei Tumori","Milan","20133",{"type":30,"coordinates":62},[63,64],12.59836,42.78235,{"lat":64,"lon":63},[67,71,75],{"name":68,"role":14,"phone":69,"phoneExt":7,"email":70},"Paolo Corradini, MD","+39 0223902950","paolo.corradini@unimi.it",{"name":72,"role":14,"phone":73,"phoneExt":7,"email":74},"Anna Guidetti, MD","+39 0223902175","anna.guidetti@istitutotumori.mi.it",{"name":68,"role":11,"phone":7,"phoneExt":7,"email":7},{"type":77,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100576142","study-in-patients-with-relapsedrefractory-primary-mediastinal-lymphoma-treated-with-pembrolizumab-or-nivolumab-in-combination-with-brentuximab-vedotin-in-a-real-life-context-100576142",false,"NCT06781450","Study in Patients With Relapsed\u002FRefractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context","Retrospective Observational Study in Patients With Relapsed \u002F Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context","PRIMICI","Inclusion Criteria:\n\n1. Histologically confirmed diagnosis of Primary Mediastinal B Cell Lymphoma Relapsed\u002FRefractory patients who underwent pembrolizumab as a single agent and nivolumab in combination with brentuximab vedotin in a real-life context with till Novembre 2021\n2. Age ≥ 18 years at enrollment\n3. Signature of written informed consent (where applicable)\n\nExclusion Criteria:\n\n1\\. Primary Mediastinal B Cell Lymphoma Relapsed\u002FRefractory patients who underwent pembrolizumab as a single agent and nivolumab in combination with brentuximab vedotin in a clinical trial context.","ALL","18 Years",{"count":89,"type":90},50,"ESTIMATED","OBSERVATIONAL","Observational, Non-Interventional, Retrospective, Multicenter Study Focusing on the Efficacy and Safety of Pembrolizumab Monotherapy and Nivolumab in Combination With Brentuximab Vedotin in Clinical Practice Patients With Primary Mediastinal B Cell Lymphoma Relapsed\u002FRefractory",[94],"Primary Mediastinal B Cell Lymphoma",[96,97,98],"pembrolizumab","nivolumab","brentuximab vedotin","2025-01-28",{"date":101,"type":102},"2025-01-30","ACTUAL",{"date":104,"type":102},"2022-04-23",{"date":106,"type":90},"2025-12",{"name":5,"class":6},3]